Inhibition of GSK-3 beta
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 20, 2001
app pub date -
Dec 22, 2000
filing date -
Dec 23, 1999
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The activity of NF-.kappa.B is modulated through the effects of GSK-3 on NF-.kappa.B activity. Inhibition or down-regulation of GSK-3 results in decreased NF-.kappa.B activity. Inappropriate activation of NF-.kappa.B has been linked to inflammation and hyperproliferative disorders. Development of modulatory strategies provide a novel therapeutic tool for the treatment or prevention of various diseases. Methods are also provided for enhanced killing of tumor cells through the sensitization action of GSK-3 inhibition, when administered in conjunction with apoptosis inducing ligands of TNFR1. Transgenic animals defective in GSK-3 function are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully